BioPorto A/S (CPH:BIOPOR)

Revenue by Segment

Financials in millions DKK. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
NGAL Tests	28.22M	23.05M	18.56M	14.86M	12.35M
NGAL Tests Growth	22.43%	24.23%	24.91%	20.29%	-8.03%
Antibodies	10.54M	10.78M	10.68M	12.03M	9.29M
Antibodies Growth	-2.30%	0.95%	-11.24%	29.51%	36.81%
ELISA Kits	1.38M	2.27M	1.67M	1.84M	2.55M
ELISA Kits Growth	-39.18%	35.54%	-8.82%	-27.94%	0.28%
Royalty and Other Revenue	148.00K	137.00K	45.00K	243.00K	64.00K
Royalty and Other Revenue Growth	8.03%	204.44%	-81.48%	279.69%	236.84%
Total	40.29M	36.24M	30.96M	28.97M	24.25M
Total Growth	11.16%	17.07%	6.87%	19.44%	4.53%

Revenue by Geography

Financials in millions DKK. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
North America	24.18M	20.63M	17.48M	14.95M	13.45M
North America Growth	17.18%	18.05%	16.89%	11.17%	29.66%
Denmark, and Rest of Europe	12.23M	10.24M	-	-	-
Denmark, and Rest of Europe Growth	19.44%	-	-	-	-
Asia	3.88M	5.37M	3.77M	3.92M	3.07M
Asia Growth	-27.74%	42.34%	-3.70%	27.86%	9.23%
Other	-	-	-	7.00K	30.00K
Other Growth	-	-	-	-76.67%	275.00%
Europe	-	-	9.71M	10.09M	7.71M
Europe Growth	-	-	-3.82%	30.90%	-23.04%
Total	40.29M	36.24M	30.96M	28.97M	24.25M
Total Growth	11.16%	17.07%	6.87%	19.44%	4.53%

Source: S&P Global Market Intelligence.